Literature DB >> 10768555

Cerebral metabolic response to passive audiovisual stimulation in patients with Alzheimer's disease and healthy volunteers assessed by PET.

P Pietrini1, G E Alexander, M L Furey, A Dani, M J Mentis, B Horwitz, M Guazzelli, M B Shapiro, S I Rapoport.   

Abstract

UNLABELLED: Alzheimer's disease is associated with reductions in resting-state brain metabolism, as measured by PET, progressing with dementia severity. The purpose of this study was to see to what extent brain regions with reduced resting-state metabolic rates in Alzheimer patients could be activated by a passive audiovisual stimulation test and to compare the result with activation in age-matched healthy volunteers. The extent of activation in Alzheimer's disease is considered to reflect the integrity of synaptic function, or inherent viability, and the potential responsiveness of the Alzheimer brain to drug therapy.
METHODS: Regional cerebral metabolic rates for glucose (rCMRglc, in mg/ 100 g tissue/min) were measured in the resting state (eyes and ears covered) and during passive audiovisual stimulation (watching a movie) in 15 otherwise healthy Alzheimer patients of differing dementia severity (Mattis Dementia Rating Scale score, 23-128) and in 14 age-matched healthy volunteers (score, 141 +/- 3) using PET with 2 sequential injections of FDG.
RESULTS: In the volunteers, audiovisual stimulation caused significant rCMRglc increases in visual and auditory cortical areas but significant decreases in frontal areas. In the mildly demented patients, rCMRglc responses were within 2 SDs of the mean in volunteers. However, the magnitude of the rCMRglc responses during stimulation declined significantly with dementia severity in the right occipitotemporal, right and left occipital association, and left calcarine cortical regions.
CONCLUSION: Functional brain responsiveness, evaluated by a passive audiovisual stimulation paradigm with PET, is within normal limits in mildly demented Alzheimer patients but fails with worsening dementia severity. Declining responsiveness may account for the limited success of neurotransmitter replacement therapy in Alzheimer patients with moderate-to-severe dementia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10768555

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  11 in total

1.  [Functional magnetic resonance imaging and dementia].

Authors:  F L Giesel; A Hempel; P Schönknecht; T Wüstenberg; M A Weber; J Schröder; M Essig
Journal:  Radiologe       Date:  2003-06-24       Impact factor: 0.635

2.  Global cerebral blood flow in relation to cognitive performance and reserve in subjects with mild memory deficits.

Authors:  Laura L Boles Ponto; Vincent A Magnotta; David J Moser; Kevin M Duff; Susan K Schultz
Journal:  Mol Imaging Biol       Date:  2006 Nov-Dec       Impact factor: 3.488

3.  Effects of donepezil on cortical metabolic response to activation during (18)FDG-PET in Alzheimer's disease: a double-blind cross-over trial.

Authors:  Stefan J Teipel; Alexander Drzezga; Peter Bartenstein; Hans-Jürgen Möller; Markus Schwaiger; Harald Hampel
Journal:  Psychopharmacology (Berl)       Date:  2006-06-01       Impact factor: 4.530

Review 4.  Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology.

Authors:  Harald Hampel; Nicola Toschi; Claudio Babiloni; Filippo Baldacci; Keith L Black; Arun L W Bokde; René S Bun; Francesco Cacciola; Enrica Cavedo; Patrizia A Chiesa; Olivier Colliot; Cristina-Maria Coman; Bruno Dubois; Andrea Duggento; Stanley Durrleman; Maria-Teresa Ferretti; Nathalie George; Remy Genthon; Marie-Odile Habert; Karl Herholz; Yosef Koronyo; Maya Koronyo-Hamaoui; Foudil Lamari; Todd Langevin; Stéphane Lehéricy; Jean Lorenceau; Christian Neri; Robert Nisticò; Francis Nyasse-Messene; Craig Ritchie; Simone Rossi; Emiliano Santarnecchi; Olaf Sporns; Steven R Verdooner; Andrea Vergallo; Nicolas Villain; Erfan Younesi; Francesco Garaci; Simone Lista
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

5.  Dynamic functional imaging of brain glucose utilization using fPET-FDG.

Authors:  Marjorie Villien; Hsiao-Ying Wey; Joseph B Mandeville; Ciprian Catana; Jonathan R Polimeni; Christin Y Sander; Nicole R Zürcher; Daniel B Chonde; Joanna S Fowler; Bruce R Rosen; Jacob M Hooker
Journal:  Neuroimage       Date:  2014-06-14       Impact factor: 6.556

Review 6.  A new integrative model of cerebral activation, deactivation and default mode function in Alzheimer's disease.

Authors:  Marc Wermke; Christian Sorg; Afra M Wohlschläger; Alexander Drzezga
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03       Impact factor: 9.236

Review 7.  Coupled reductions in brain oxidative phosphorylation and synaptic function can be quantified and staged in the course of Alzheimer disease.

Authors:  Stanley I Rapoport
Journal:  Neurotox Res       Date:  2003       Impact factor: 3.978

8.  APOE Genotype Effects on Intrinsic Brain Network Connectivity in Patients with Amnestic Mild Cognitive Impairment.

Authors:  Zan Wang; Zhengjia Dai; Hao Shu; Xuhong Liao; Chunxian Yue; Duan Liu; Qihao Guo; Yong He; Zhijun Zhang
Journal:  Sci Rep       Date:  2017-03-24       Impact factor: 4.379

9.  Cholinesterase inhibition modulates visual and attentional brain responses in Alzheimer's disease and health.

Authors:  Paul Bentley; Jon Driver; Ray J Dolan
Journal:  Brain       Date:  2007-12-12       Impact factor: 13.501

10.  Strategies for molecular imaging dementia and neurodegenerative diseases.

Authors:  Bernhard J Schaller
Journal:  Neuropsychiatr Dis Treat       Date:  2008-06       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.